BiotechTube

BS01

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa

Trial Timeline

Feb 6, 2020 → Dec 30, 2029

NCT ID
NCT04278131

About BS01

BS01 is a phase 1/2 stage product being developed by Bionic Sight for Retinitis Pigmentosa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04278131. Target conditions include Retinitis Pigmentosa.

What happened to similar drugs?

0 of 3 similar drugs in Retinitis Pigmentosa were approved

Approved (0) Terminated (0) Active (3)
🔄Valganciclovir + GanciclovirRochePhase 3
🔄GanciclovirRochePhase 3
🔄ValganciclovirRochePhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07158775Phase 1/2Recruiting
NCT04278131Phase 1/2Recruiting

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
39
AGN-151597AbbViePhase 1/2
32
CPK850NovartisPhase 1/2
36
Valganciclovir + GanciclovirRochePhase 3
40
ValganciclovirRochePre-clinical
26
Foscarnet sodium + GanciclovirRochePhase 1
29
GanciclovirRochePhase 1
29
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 2
35
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
26
Zidovudine + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Interferon beta-1b + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 3
40
ValganciclovirRochePhase 3
36
Cidofovir + ProbenecidGilead SciencesPre-clinical
26